Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Public ClinicalTrials.gov record NCT03056833. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Trial of Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Study identification
- NCT ID
- NCT03056833
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Ronald Buckanovich
- Other
- Enrollment
- 35 participants
Conditions and interventions
Interventions
- Carboplatin Drug
- Paclitaxel Drug
- ribociclib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 9, 2017
- Primary completion
- May 31, 2020
- Completion
- Jul 31, 2022
- Last update posted
- Sep 6, 2022
2017 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 2
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| UPMC Hillman Cancer Center Upper St. Clair | Bethel Park | Pennsylvania | 15102 | — |
| UPMC Hillman Cancer Center Arnold Palmer at Mountain View | Greensburg | Pennsylvania | 15601 | — |
| UPMC Hillman Cancer Center Arnold Palmer Medical at Norwin | Irwin | Pennsylvania | 15642 | — |
| UPMC Hillman Cancer Center Arnold Palmer at Mt Pleasant | Mount Pleasant | Pennsylvania | 15666 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| UPMC Hillman Cancer Center Passavant (OHA) | Pittsburgh | Pennsylvania | 15237 | — |
| UPMC Hillman Cancer Center Washington | Washington | Pennsylvania | 15301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03056833, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 6, 2022 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03056833 live on ClinicalTrials.gov.